Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Key Takeaways Moderna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory syncytial virus (RSV) vaccine. The biotech reported it was advised by regulators that their review wouldn't be completed until the …